KRAS and colorectal carcinoma: Across six KRAS-mutant metastatic CRC PDOs, including paired primary and recurrent lesions from one patient, LS-1-2 suppressed growth in a dose-dependent manner despite substantial heterogeneity in baseline chemosensitivity to conventional agents (5-FU IC50: 32.82-1143 μM; oxaliplatin IC50: 19.02-3341 μM) (Figure 2E).